ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
LillyEli & Co

LillyEli & Co (LLY)

982,70
13,60
(1,40%)
Geschlossen 06 Juni 10:00PM

LillyEli & Co (LLY) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
982,70
( 1,40% )
Gebot
980,70
Fragen
985,50
Volumen
3.581
966,50 Tagesbereich 1.009,80
535,40 52-Wochen-Bereich 1.009,80
Marktkapitalisierung
Handelsende
969,10
Handelsbeginn
967,40
Letzte Trade
3
@
982.2
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
3.081.260 €
Ausgegebene Aktien
891.741.406
Dividendenrendite (LTM)
6,23 (0,72%)
Kurs-Gewinn-Verhältnis
40,03
Gewinn pro Aktie (EPS)
28,15
Erlöse (LTM)
72,25B
Nettogewinn (LTM)
25,28B

Über LillyEli & Co

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalo... Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin’s lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer’s disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Mehr anzeigen

Sektor
Healthcare
Branche
Pharmaceuticals
Website
Hauptsitz
Indianapolis, United States
Gegründet
1876
LillyEli & Co is listed in the Healthcare sector of the Tradegate (DE) with ticker LLY. The last closing price for LillyEli & was 969,10 €. Over the last year, LillyEli & shares have traded in a share price range of 535,40 € to 1.009,80 €.

LillyEli & currently has 891.741.406 shares in issue. The market capitalisation of LillyEli & is 876,31 € billion. LillyEli & has a price to earnings ratio (PE ratio) of 40.03.

LLY Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
112.81.31972368285969.91009.8903.92426939.50757501DE
4153.618.5261126523829.11009.8802.22280904.90409631DE
12132.615.5981649218850.11009.8727.32393832.57433345DE
26112.712.95402298858701009.8727.32598864.96515354DE
52310.4000146.1698668179672.299991009.8535.43229757.69550005DE
156568.1137.023637241414.61009.840.434030712.86080172DE
260818.15497.204497113164.551009.840.432709664.16822422DE

LLY - Frequently Asked Questions (FAQ)

What is the current LillyEli & Co share price?
The current share price of LillyEli & Co is 982,70 €
How many LillyEli & Co shares are in issue?
LillyEli & Co has 891.741.406 shares in issue
What is the market cap of LillyEli & Co?
The market capitalisation of LillyEli & Co is EUR 876,31B
What is the 1 year trading range for LillyEli & Co share price?
LillyEli & Co has traded in the range of 535,40 € to 1.009,80 € during the past year
What is the PE ratio of LillyEli & Co?
The price to earnings ratio of LillyEli & Co is 40,03
What is the cash to sales ratio of LillyEli & Co?
The cash to sales ratio of LillyEli & Co is 13,91
What is the registered address of LillyEli & Co?
The registered address for LillyEli & Co is Lilly Corporate Center, Indianapolis, Indiana, 46285
What is the LillyEli & Co website address?
The website address for LillyEli & Co is www.lilly.com
Which industry sector does LillyEli & Co operate in?
LillyEli & Co operates in the Pharmaceuticals sector

LLY Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen